c-Abl Antibody from Cell Signaling Technology

Yes, the c-Abl antibody has been shown to be involved in the recruitment of c-Abl to the p53-DNA complex following exposure to alkylating agents, which is critical for the cellular response to DNA damage. This was highlighted in a study where the presence of c-Abl was linked to the modulation of DNA repair processes and cell survival after treatment with the alkylating agent MNNG (ahkoon2016).

The c-Abl antibody has been utilized in multiple studies involving cancer models, particularly in the context of chronic myelogenous leukemia (CML). For instance, it has been used to assess the effects of various treatments on Bcr-Abl protein levels and signaling pathways in leukemic cells, demonstrating its effectiveness in cancer research (bucur2013, tao2015).

The c-Abl antibody is suitable for applications such as Western blotting and immunoprecipitation. It has been cited in numerous studies that utilize these techniques to analyze c-Abl protein levels and its phosphorylation status in various cellular contexts (hawez2022, mcdaniel2020).

Yes, studies have indicated that targeting c-Abl can enhance the efficacy of therapeutic strategies in leukemia, particularly in overcoming resistance to tyrosine kinase inhibitors. The c-Abl antibody has been used to investigate the effects of combined treatments that aim to downregulate Bcr-Abl and its associated signaling pathways, which are crucial for the survival of leukemic cells (chakrabo2016, zhang2023).